These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 38898120)

  • 21. Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).
    Drilon A; Siena S; Ou SI; Patel M; Ahn MJ; Lee J; Bauer TM; Farago AF; Wheler JJ; Liu SV; Doebele R; Giannetta L; Cerea G; Marrapese G; Schirru M; Amatu A; Bencardino K; Palmeri L; Sartore-Bianchi A; Vanzulli A; Cresta S; Damian S; Duca M; Ardini E; Li G; Christiansen J; Kowalski K; Johnson AD; Patel R; Luo D; Chow-Maneval E; Hornby Z; Multani PS; Shaw AT; De Braud FG
    Cancer Discov; 2017 Apr; 7(4):400-409. PubMed ID: 28183697
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.
    Shaw AT; Felip E; Bauer TM; Besse B; Navarro A; Postel-Vinay S; Gainor JF; Johnson M; Dietrich J; James LP; Clancy JS; Chen J; Martini JF; Abbattista A; Solomon BJ
    Lancet Oncol; 2017 Dec; 18(12):1590-1599. PubMed ID: 29074098
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001.
    Shaw AT; Riely GJ; Bang YJ; Kim DW; Camidge DR; Solomon BJ; Varella-Garcia M; Iafrate AJ; Shapiro GI; Usari T; Wang SC; Wilner KD; Clark JW; Ou SI
    Ann Oncol; 2019 Jul; 30(7):1121-1126. PubMed ID: 30980071
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effectiveness of crizotinib versus entrectinib in
    Tremblay G; Groff M; Iadeluca L; Daniele P; Wilner K; Wiltshire R; Bartolome L; Usari T; Cappelleri JC; Camidge DR
    Future Oncol; 2022 Jun; 18(17):2063-2074. PubMed ID: 35232230
    [No Abstract]   [Full Text] [Related]  

  • 25. FDA Approval Summary: Repotrectinib for Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer.
    Barbato MI; Bradford D; Ren Y; Aungst SL; Miller CP; Pan L; Zirkelbach JF; Li Y; Bi Y; Fan J; Grimstein M; Dorff SE; Amatya AK; Mishra-Kalyani PS; Scepura B; Schotland P; Udoka O; Ojofeitimi I; Leighton JK; Rahman NA; Pazdur R; Singh H; Kluetz PG; Drezner N
    Clin Cancer Res; 2024 Aug; 30(16):3364-3370. PubMed ID: 38875108
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Updated efficacy and safety of entrectinib in NTRK fusion-positive non-small cell lung cancer.
    Cho BC; Chiu CH; Massarelli E; Buchschacher GL; Goto K; Overbeck TR; Loong HHF; Chee CE; Garrido P; Dong X; Fan Y; Lu S; Schwemmers S; Bordogna W; Zeuner H; Osborne S; John T
    Lung Cancer; 2024 Feb; 188():107442. PubMed ID: 38171156
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of detection methods and follow-up study on the tyrosine kinase inhibitors therapy in non-small cell lung cancer patients with ROS1 fusion rearrangement.
    Wu J; Lin Y; He X; Yang H; He P; Fu X; Li G; Gu X
    BMC Cancer; 2016 Aug; 16():599. PubMed ID: 27488371
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinicopathologic, genomic and protein expression characterization of 356 ROS1 fusion driven solid tumors cases.
    Huang RSP; Haberberger J; Sokol E; Schrock AB; Danziger N; Madison R; Trabucco S; Jin D; Pavlick D; Ramanan V; Hole K; McGregor K; Venstrom J; Ross JS
    Int J Cancer; 2021 Apr; 148(7):1778-1788. PubMed ID: 33336398
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Blood First Assay Screening Trial (BFAST) in Treatment-Naive Advanced or Metastatic NSCLC: Initial Results of the Phase 2 ALK-Positive Cohort.
    Dziadziuszko R; Mok T; Peters S; Han JY; Alatorre-Alexander J; Leighl N; Sriuranpong V; Pérol M; de Castro Junior G; Nadal E; de Marinis F; Frontera OA; Tan DSW; Lee DH; Kim HR; Yan M; Riehl T; Schleifman E; Paul SM; Mocci S; Patel R; Assaf ZJ; Shames DS; Mathisen MS; Gadgeel SM
    J Thorac Oncol; 2021 Dec; 16(12):2040-2050. PubMed ID: 34311110
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Crizotinib in ROS1-rearranged non-small-cell lung cancer.
    Shaw AT; Ou SH; Bang YJ; Camidge DR; Solomon BJ; Salgia R; Riely GJ; Varella-Garcia M; Shapiro GI; Costa DB; Doebele RC; Le LP; Zheng Z; Tan W; Stephenson P; Shreeve SM; Tye LM; Christensen JG; Wilner KD; Clark JW; Iafrate AJ
    N Engl J Med; 2014 Nov; 371(21):1963-71. PubMed ID: 25264305
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety exposure-response analyses of entrectinib in patients with advanced or metastatic solid tumors.
    Mercier F; Djebli N; González-Sales M; Jaminion F; Meneses-Lorente G
    Cancer Chemother Pharmacol; 2022 Mar; 89(3):363-372. PubMed ID: 35118559
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial.
    Shaw AT; Solomon BJ; Chiari R; Riely GJ; Besse B; Soo RA; Kao S; Lin CC; Bauer TM; Clancy JS; Thurm H; Martini JF; Peltz G; Abbattista A; Li S; Ou SI
    Lancet Oncol; 2019 Dec; 20(12):1691-1701. PubMed ID: 31669155
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Matching-adjusted indirect comparison: entrectinib versus crizotinib in
    Chu P; Antoniou M; Bhutani MK; Aziez A; Daigl M
    J Comp Eff Res; 2020 Aug; 9(12):861-876. PubMed ID: 32648475
    [No Abstract]   [Full Text] [Related]  

  • 34. Current treatment and future challenges in ROS1- and ALK-rearranged advanced non-small cell lung cancer.
    Remon J; Pignataro D; Novello S; Passiglia F
    Cancer Treat Rev; 2021 Apr; 95():102178. PubMed ID: 33743408
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biomarker guided treatment in oncogene-driven advanced non-small cell lung cancer in older adults: A Young International Society of Geriatric Oncology report.
    Christofyllakis K; Monteiro AR; Cetin O; Kos IA; Greystoke A; Luciani A
    J Geriatr Oncol; 2022 Nov; 13(8):1071-1083. PubMed ID: 35525790
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A case of lung adenocarcinoma with a novel CD74-ROS1 fusion variant identified by comprehensive genomic profiling that responded to crizotinib and entrectinib.
    Hashiguchi MH; Sato T; Watanabe R; Kagyo J; Matsuzaki T; Domoto H; Kato T; Nakahara Y; Yokose T; Hiroshima Y; Shiomi T
    Thorac Cancer; 2021 Sep; 12(18):2504-2507. PubMed ID: 34319660
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lung Injury Induced by Crizotinib and Entrectinib in a Patient with ROS1-rearranged Non-small-cell Lung Cancer.
    Nishiyama Y; Omori S; Matsumoto H; Komiya K; Hiramatsu K
    Intern Med; 2023 Dec; 62(23):3507-3510. PubMed ID: 37062732
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer.
    Farago AF; Le LP; Zheng Z; Muzikansky A; Drilon A; Patel M; Bauer TM; Liu SV; Ou SH; Jackman D; Costa DB; Multani PS; Li GG; Hornby Z; Chow-Maneval E; Luo D; Lim JE; Iafrate AJ; Shaw AT
    J Thorac Oncol; 2015 Dec; 10(12):1670-4. PubMed ID: 26565381
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
    Solomon BJ; Besse B; Bauer TM; Felip E; Soo RA; Camidge DR; Chiari R; Bearz A; Lin CC; Gadgeel SM; Riely GJ; Tan EH; Seto T; James LP; Clancy JS; Abbattista A; Martini JF; Chen J; Peltz G; Thurm H; Ou SI; Shaw AT
    Lancet Oncol; 2018 Dec; 19(12):1654-1667. PubMed ID: 30413378
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Highly sensitive fusion detection using plasma cell-free RNA in non-small-cell lung cancers.
    Hasegawa N; Kohsaka S; Kurokawa K; Shinno Y; Takeda Nakamura I; Ueno T; Kojima S; Kawazu M; Suehara Y; Ishijima M; Goto Y; Kojima Y; Yonemori K; Hayashi T; Saito T; Shukuya T; Takahashi F; Takahashi K; Mano H
    Cancer Sci; 2021 Oct; 112(10):4393-4403. PubMed ID: 34310819
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.